Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prolor Biotech has reported the positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa, Factor VIIa-CTP in hemophilic mice.
Subscribe to our email newsletter
The comparative study will evaluate the potential increase in survival rates, thrombin levels and in vivo recovery of Factor VIIa-CTP.
The study reported that Factor VIIa-CTP showed superior survival rate over a longer time period following a bleeding challenge, superior and longer-lasting generation of thrombin, a key pro-clotting enzyme and higher in vivo recovery.
Prolor CEO Abraham Havron said the preclinical hemophilia studies suggested that Factor VIIa-CTP may offer an improved therapeutic option for hemophiliacs by reducing the frequency of injections, controlling bleeding and improving quality of life.
Factor VIIa-CTP has demonstrated positive results in an earlier comparative study compared to commercially available Factor VIIa.